Full-Time

Sr Scientist

Innovation Lab

Posted on 10/31/2025

Tarsus Pharamceuticals

Tarsus Pharamceuticals

201-500 employees

Biopharma developing eye-care therapies

Compensation Overview

$116.2k - $162.8k/yr

+ Bonus + Stock Equity

Irvine, CA, USA

Hybrid

Hybrid work environment; some travel up to 30%.

Category
Lab & Research (3)
, ,
Requirements
  • PhD with 2+ years of experience in the life science industry required, OR MS with 6+ years life sciences experience, OR BS with 8+ years life sciences experience
  • Experience designing and executing preclinical studies, with expertise in in vitro techniques and cell/tissue culture
  • Experience managing external research collaborations (CROs or academic partnerships) and multiple concurrent projects
  • Strong analytical skills for interpreting complex data, with ability to clearly communicate scientific findings
  • Self-motivated with the ability to work independently while aligning with strategic objectives
  • Experience setting up or managing laboratory operations
Responsibilities
  • Serve as the expert scientific voice on the Innovation team, responsible for designing the scientific strategy and experimental plans required to meet goals set by leadership
  • Identify, establish, and provide strategic oversight for external research collaborations, serving as an advisor to scientists on relationship management
  • Lead the design, validation, and scientific oversight of experimental protocols, serving as the technical source of truth for the team
  • Coordinate with external partners on in vivo ophthalmology models for efficacy, pharmacokinetics, and toxicity studies
  • Oversee the execution of experiments in our internal lab while also conducting experiments where necessary
  • Conduct basic science and clinical literature reviews, and be able to succinctly summarize in presentations disease pathophysiologic mechanisms and potential translation of various therapies
  • Lead the analysis and interpretation of complex data sets, and present key findings and strategic recommendations to cross-functional teams and leadership
  • Contribute to the continued development of our laboratory infrastructure
  • Serve as a key scientific advisor on cross-functional initiatives, providing in-depth program evaluation to support diligence efforts
  • Formally manage, mentor, and develop a team of scientists
  • Lead the overall development of laboratory infrastructure, with the expectation to delegate specific operational responsibilities to the scientific team over time
  • Stay current with scientific and medical literature in relevant therapeutic areas
Desired Qualifications
  • The position will be based in Irvine office, complete with a courtyard, snacks, drinks, and occasional catered meals. We provide a hybrid work environment
  • Some travel may be required – up to 30%
  • Prior experience mentoring, supervising, or managing junior scientific staff
  • Scientific ophthalmology experience highly preferred
Tarsus Pharamceuticals

Tarsus Pharamceuticals

View

Tarsus Pharmaceuticals develops treatments for eye care and infectious diseases. Its FDA-approved product, XDEMVY (lotilaner ophthalmic solution 0.25%), treats Demodex Blepharitis by killing Demodex mites on the eyelids. The company also has a pipeline targeting conditions like Lyme Disease Prevention, Meibomian Gland Disease, and Rosacea, and it earns revenue from selling approved products and collaborating with partners. Its goal is to address unmet medical needs by developing, commercializing, and expanding collaborations to reach more patients.

Company Size

201-500

Company Stage

IPO

Headquarters

Irvine, California

Founded

2017

Simplify Jobs

Simplify's Take

What believers are saying

  • XDEMVY nets $145 million Q1 2026 sales, up 85% year-over-year.
  • 2026 guidance projects $670-$700 million XDEMVY sales, 50% growth.
  • $200 million Pharmakon financing supports sales force expansion without dilution.

What critics are saying

  • ICRx Cliradex wipes erode XDEMVY sales by 15-20% within 6-12 months.
  • TP-05 CALLIOPE trial fails efficacy, halts Phase 3 in 12-18 months.
  • Aldeyra reproxalap captures 25% Demodex market share post-2027 approval.

What makes Tarsus Pharamceuticals unique

  • XDEMVY is the only FDA-approved treatment for Demodex blepharitis.
  • TP-05 advances as first-in-class oral Lyme disease preventive in Phase 2 CALLIOPE trial.
  • TP-04 targets untreated ocular rosacea market in Phase 2 with H1 2027 data.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Paid Vacation

Hybrid Work Options

Professional Development Budget

Growth & Insights and Company News

Headcount

6 month growth

-1%

1 year growth

0%

2 year growth

2%
Yahoo Finance
Apr 3rd, 2026
Tarsus Pharmaceuticals doses first patient in Phase 2 Lyme disease prevention trial with TP-05

Tarsus Pharmaceuticals has dosed the first participant in its Phase 2 Calliope trial of TP-05, an investigational oral therapy aimed at preventing Lyme disease in approximately 700 at-risk adults across endemic US regions. The programme targets a significant unmet need as a potential first-in-class, non-vaccine prophylactic for Lyme disease, where no FDA-approved preventive drugs currently exist. Whilst the trial marks progress, near-term investment focus remains on XDEMVY adoption and margins. The company recently received a $15 million milestone payment tied to TP-03 approval in China, highlighting monetisation of its lotilaner platform beyond the US. Analyst projections for Tarsus vary widely, with some forecasting $847 million revenue and $237 million earnings by 2028, whilst more cautious estimates suggest $988 million revenue and $188 million earnings by 2029.

Yahoo Finance
Mar 24th, 2026
Tarsus Pharma CHRO sells $839K in shares via mandatory RSU vesting amid 20% stock surge

Dianne Whitfield, Chief Human Resources Officer at Tarsus Pharmaceuticals, sold 12,274 shares of common stock worth approximately $839,000 between 17 and 19 March 2026. The sale represented 25.95% of her direct holdings, reducing her position from 47,302 to 35,028 shares. The transaction was a mandatory "sell to cover" arrangement tied to RSU vesting for tax withholding purposes, rather than a discretionary sale. Shares sold at a weighted average price of $68.36. Tarsus Pharmaceuticals generated $451.4 million in net product sales in 2025, more than doubling from the prior year, driven by adoption of its lead product XDEMVY. The company narrowed its net loss to $66.4 million and ended 2025 with over $417 million in cash and marketable securities.

Yahoo Finance
Feb 24th, 2026
Tarsus Pharmaceuticals projects $670M–$700M 2026 sales as XDEMVY hits profitability

Tarsus Pharmaceuticals reported $450 million in full-year net sales for 2025, with its XDEMVY treatment achieving product-line profitability. The company has expanded its addressable market from nine million to 25 million Americans with Demodex blepharitis as screening becomes routine amongst eye care professionals. The firm projected 2026 net product sales between $670 million and $700 million, representing approximately 50% annual growth at the midpoint. Direct-to-consumer awareness reached 25% amongst surveyed patients, significantly increasing treatment requests. Tarsus plans to expand its sales force by 15 to 20 key account leaders and will initiate a Phase II trial for TP-05 in Lyme disease prevention in Q2 2026. The company has also launched the first Phase II trial for TP-04 in Ocular Rosacea, a category with no currently approved FDA treatments.

GlobeNewswire
Mar 13th, 2025
Tarsus Announces Pricing of Upsized $125.0 Million Public Offering

IRVINE, Calif., March 12, 2025 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (Nasdaq: TARS) (the “Company” or “Tarsus”) today announced the pricing of...

MarketBeat
Nov 22nd, 2024
Mutual of America Capital Management LLC Invests $4.29 Million in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)

Mutual of America Capital Management LLC invests $4.29 million in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS).

INACTIVE